



**AWTTC**

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

## **The New Treatment Fund**

**Medicines Recommended by NICE and AWMSG:  
Health Board Formulary Status  
(From 1 January 2017 to 31 January 2019)**

## **EXECUTIVE SUMMARY**

Of the 155 medicines within the New Treatment Fund which were recommended more than 60 days ago, all health boards had at least 95% of these medicines on formulary within 60 days.

Of the 155 medicines within the New Treatment Fund which were recommended more than 60 days ago, an average of 12 days was taken to add these to formularies.

Of the 11 medicines within the New Treatment Fund which were recommended within the last 60 days, four health boards had at least 64% of these medicines on formulary.

Of the 166 medicines within the New Treatment Fund, all health boards had at least 95% of these medicines on formulary.

## **BACKGROUND**

The Welsh Government launched the New Treatment Fund in January 2017. The fund provides an additional £16 million annually for health boards and trusts in Wales to support the faster introduction of new medicines recommended by the National Institute for Health and Care Excellence (NICE) and the All Wales Medicines Strategy Group (AWMSG).

The New Treatment Fund requires the seven health boards and one NHS trust to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of the publication of the decision. For NICE recommendations, a medicine should be available no later than 60 calendar days after the first publication of the Final Appraisal Determination (FAD), or the Final Evaluation Determination (FED) for Highly Specialised Technologies (HSTs). For AWMSG recommendations, a medicine should be available no later than 60 calendar days after ratification of the recommendation by the Welsh Government. Occasionally the start of the 60 day timescale may be delayed because a Commercial Access Agreement (CAA) has not yet been agreed. In such circumstances this is indicated within the report. NICE and AWMSG may recommend an entirely new medicine, or a new use of an existing medicine to treat a different condition, for routine use in the NHS. Although recommended medicines should be made available within 60 days of recommendation, the sooner they are available, the sooner they can be prescribed where clinically appropriate.

In April 2017 the Welsh Government issued revised directions for health boards and NHS trusts, with an accompanying Welsh Health Circular, *The New Treatment Fund – Access to medicines recommended by NICE and AWMSG* (WHC [2017] 001).

A health board formulary is an official list of medicines which may be prescribed within the health board to treat patients. Until a medicine is added to the formulary, prescribers may not be aware that it is available for use.

This document reports on the formulary status of medicines recommended for use within NHS Wales by NICE and AWMSG. All data in this report is as of 31 January 2019.

## **SOURCE OF INFORMATION**

Across Wales, six of the seven health boards use the online “Inform” formulary software programme provided and maintained by the NHS Wales Informatics Service (NWIS). Abertawe Bro Morgannwg University Health Board (UHB) and Velindre NHS Trust (Velindre Cancer Centre) have separate formulary systems. Velindre NHS Trust treats certain types of cancers only; the report therefore only takes account of those medicines clinically appropriate for inclusion on the trust formulary.

This report has been compiled through a combination of an analysis of health board formularies and the submission of data and additional information from Chief Pharmacists.

**Table 1. Formulary status and time elapsed since latest AWMMSG/NICE recommendation for New treatment Fund medicines (31 January 2019)**

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status <sup>^#</sup>						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
11/01/17		TA427	2590	Pomalidomide	Multiple myeloma	-	-	1	-	-	30	78
11/01/17		TA428		Pembrolizumab	Lung cancer (previously treated)	1	-	1	65	100	27	78
25/01/17		TA429		Ibrutinib	Leukaemia	1	-	1	50	51	1	64
25/01/17		TA430	2417	Sofosbuvir/velpatasvir	Hepatitis C	-	-	1	-	51	1	-
25/01/17		TA431		Mepolizumab	Asthma	1	-	1	68	51	13	64
07/02/17		ID758 (HST6)		Asfotase alfa	Hypophosphatasia	0	153	30	0	149	2	156
22/02/17		HST4		Migalastat	Fabry disease	0	40	30	0	41	135	140
22/02/17		TA432		Everolimus	Renal cancer	-	0	1	-	-	-	69
22/02/17		TA433		Apremilast	Psoriatic arthritis	-	-	1	-	23	20	-
02/03/17		ID785 (TA443)		Obeticholic acid	Biliary cirrhosis	56	-	64	117	57	20	53
02/03/17		ID794 (TA439)	2407	Cetuximab	Colorectal cancer	20	1	-	-	-	55	53
02/03/17		ID794 (TA439)	2744	Panitumumab	Colorectal cancer	27	-	1	50	57	55	53
10/03/17		ID904 (TA442)		Ixekizumab	Psoriasis	1	-	56	91	49	12	45
14/03/17		1586		Aflibercept	Choroidal neovascularisation	1	-	0	-	-	1	49
14/03/17		1658		Triptorelin	Prostate cancer	-	-	1	-	38	1	-
15/03/17		ID827 (TA441)		Daclizumab	Multiple sclerosis	42	-	1	-	44	7	-
03/04/17		2597		Idelalisib	Follicular lymphoma	1	-	0	-	39	29	29
13/04/17		ID579 (TA445)		Secukinumab	Psoriatic arthritis	11	-	1	-	19	19	11
13/04/17		ID579 (TA445)	1713	Certolizumab pegol	Psoriatic arthritis	-	-	1	-	-	19	-
27/04/17		ID843 (TA456)		Ustekinumab	Crohn's disease	1	7	34	-	40	43	7
27/04/17		ID804 (TA450)	589	Blinatumomab	Leukaemia	-	-	-	-	40	43	7
28/04/17		ID722 (TA446)	1255	Brentuximab vedotin	Hodgkin lymphoma	-	-	-	-	-	4	42
28/04/17		ID671 (TA451)	1163	Ponatinib	Leukaemia	-	-	-	-	-	42	6
12/05/17		ID858 (TA449)	390	Sunitinib	Neuroendocrine tumours	-	0	-	-	-	28	28
12/05/17		ID858 (TA449)	142	Everolimus	Neuroendocrine tumours	-	0	19	-	-	28	28
19/05/17		ID908 (TA448)		Etelcalcetide	Hyperparathyroidism	1	5	12	46	17	49	21
31/05/17		ID709 (HST5)		Eliglustat	Gaucher disease	0	40	37	0	6	37	37
31/05/17	28/07/17	ID990 (TA447)		Pembrolizumab	Lung cancer (previously untreated)	60	10	37	64	0	-	10
02/06/17		ID763 (TA460)		Adalimumab	Uveitis	-	19	18	-	28	19	-
02/06/17		ID763 (TA460)		Dexamethasone	Uveitis	-	14	-	-	28	19	-
02/06/17		ID972 (TA462)		Nivolumab	Hodgkin lymphoma	0	6	18	-	28	19	1
09/06/17		ID837 (TA504)		Pirfenidone	Idiopathic pulmonary fibrosis	-	3	11	-	-	12	-
09/06/17		ID934 (TA457)		Carfilzomib	Multiple myeloma	4	10	10	41	13	12	1
09/06/17	23/06/17	ID959 (TA465)		Olaratumab	Sarcoma	25	3	11	24	0	12	1

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
09/06/17		ID854 (TA455)		Etanercept	Psoriasis	-	33	11	-	20	12	-
09/06/17		ID854 (TA455)	2068	Ustekinumab	Psoriasis	-	33	11	-	20	12	-
09/06/17		ID854 (TA455)	2571	Adalimumab	Psoriasis	-	33	11	-	20	12	-
15/06/17	19/06/17	ID1013 (TA458)		Trastuzumab emtansine	Breast cancer	6	4	11	18	4	6	1
22/06/17		ID984 (TA461)		Roflumilast	Chronic obstructive pulmonary disease	0	7	2	56	4	8	1
22/06/17		ID621 (TA459)	930	Collagenase clostridium histolyticum	Dupuytren's contracture	-	7	-	-	-	-	1
29/06/17		ID979 (TA466)		Baricitinib	Rheumatoid arthritis	5	1	5	50	1	8	1
07/07/17		ID899 (TA467)		Holoclax	Eye burns	40	31	6	48	7	45	42
10/07/17		ID931 (TA463)		Cabozantinib	Renal cancer	0	2	1	-	2	31	-
10/07/17		ID782 (TA464)		Alendronic acid (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Ibandronic acid (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Risedronate sodium (oral)	Osteoporosis	-	0	33	-	-	-	-
10/07/17		ID782 (TA464)		Ibandronic acid (IV)	Osteoporosis	-	0	8	-	-	-	-
10/07/17		ID782 (TA464)		Zoledronic acid (IV)	Osteoporosis	-	0	33	-	-	-	-
12/07/17		3435		Aviptadil phentolamine	Erectile dysfunction	0	6	14	36	6	31	37
20/07/17		ID872 (TA479)		Reslizumab	Asthma	16	11	12	28	8	50	29
26/07/17		ID841 (TA472)		Obinutuzumab	Follicular lymphoma	14	16	4	23	2	26	23
27/07/17		ID870 (TA471)		Eluxadolone	Irritable bowel syndrome	0	11	4	22	22	20	22
04/08/17		ID776 (TA475)		Dimethyl fumarate	Psoriasis	-	7	4	20	14	13	13
04/08/17		ID1058 (TA476)	1999	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer	-	0	4	-	14	-	13
07/08/17		3371		Adalimumab	Acne inversa	-	4	4	-	11	10	-
07/08/17		2224		Cefuroxime	Eye inflammation	-	4	11	46	-	-	11
07/08/17		2527		Triamcinolone hexacetonide	Juvenile idiopathic arthritis	-	4	1	46	11	10	11
08/08/17		ID1016 (TA473)		Cetuximab	Head and neck cancer	0	3	3	-	10	1	-
10/08/17		ID1012 (TA474)	284	Sorafenib	Liver cancer	0	0	3	-	-	-	8
24/08/17		ID512 (TA478)		Brentuximab vedotin	Lymphoma	0	7	7	-	11	-	15
07/09/17		ID456(TA481), ID346 (TA482)		Basiliximab	Immunosuppression (kidney transplant)	-	0	27	-	-	-	-
07/09/17		ID456(TA481), ID346 (TA482)		Tacrolimus (immediate release)	Immunosuppression (kidney transplant)	-	0	27	-	-	-	-
07/09/17		ID456(TA481), ID346 (TA482)		Mycophenolate mofetil	Immunosuppression (kidney transplant)	-	0	27	-	-	-	-
08/09/17		ID526 (TA480)		Tofacitinib	Rheumatoid arthritis	0	3	26	41	3	47	28
20/09/17	09/10/17	ID900 (TA484)		Nivolumab	Lung cancer (non-squamous)	46	0	13	-	0	16	-

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
20/09/17	09/10/17	ID811 (TA483)		Nivolumab	Lung cancer (squamous)	46	0	13	-	0	16	-
22/09/17		ID952 (TA486)	1586	Aflibercept	Choroidal neovascularisation	-	0	10	-	-	0	-
22/09/17	04/10/17	ID994 (TA485)		Sarilumab	Rheumatoid arthritis	12	5	10	37	0	20	14
28/09/17	27/10/17	ID884 (TA491)		Ibrutinib	Waldenstrom's macroglobinaemia	0	4	5	42	0	8	-
05/10/17	27/10/17	ID944 (TA487)		Venetoclax	Leukaemia	22	7	4	42	0	14	12
10/10/17		2680		Ivacaftor	Cystic fibrosis	0	27	24	-	3	31	-
12/10/17		ID1056 (TA488)	1018	Regorafenib	Gastrointestinal cancer (sarcoma)	-	14	-	-	1	0	27
13/10/17		ID971 (TA490)		Nivolumab	Head and neck cancer (squamous)	22	5	21	0	5	28	-
17/10/17		3282		Desmopressin	Nocturia	0	8	17	41	22	24	-
19/10/17		3372		5-aminolaevulinic acid	Skin cancer	0	6	17	-	20	22	26
19/10/17		3295		C1 inhibitor	Angioedema	0	6	17	-	-	0	-
19/10/17		3373		Dolutegravir	HIV	0	6	17	-	-	22	20
19/10/17		3007	3007	Glecaprevir/pibrentasvir	Hepatitis C	0	29	22	28	20	22	20
19/10/17		976		Lenvatinib	Thyroid cancer	0	6	17	4	20	22	-
19/10/17		3436		Tiotropium	Asthma	0	4	17	-	20	0	20
01/11/17		ID939 (TA492)		Atezolizumab	Urothelial cancer	0	8	9	23	7	9	7
03/11/17		ID64 (TA493)		Cladribine	Multiple sclerosis	0	3	0	35	5	7	6
16/11/17		ID1026 (TA496)		Ribociclib	Breast cancer	0	6	25	22	1	12	26
16/11/17		ID915 (TA495)		Palbociclib	Breast cancer	0	6	25	13	1	12	26
16/11/17		ID903 (TA497)		Golimumab	Arthritis	0	0	25	-	-	25	0
28/11/17		3545		Pegvisomant	Acromegaly	0	3	13	51	6	36	14
28/11/17		3468		Stiripentol	Epilepsy	0	3	13	-	6	13	14
07/12/17		ID1085 (TA499)		Glecaprevir/pibrentasvir	Hepatitis C	0	0	1	-	-	0	0
07/12/17		ID1117 (TA500)		Ceritinib	Lung cancer	1	6	4	43	1	26	29
08/12/17		3035		Adalimumab	Eye inflammation	0	21	3	41	7	3	0
08/12/17		ID1029 (TA498)		Lenvatinib	Renal cancer	5	6	21	41	4	25	28
14/12/17	14/12/17	ID753 (TA502)		Ibrutinib	Lymphoma	4	1	15	35	5	1	56
19/12/17	12/01/18	ID807 (TA505)		Ixazomib	Multiple Myeloma	0	0	-14	34	4	4	27
17/01/18	09/02/18	ID933 (TA510)		Daratumumab	Multiple Myeloma	-3	0	-1	34	46	4	27
18/01/18	16/03/18	ID1055 (TA507)		Vosevi	Hepatitis C	0	0	-36	34	31	11	20
01/02/18	01/02/18	ID523 (TA509)		Pertuzumab	Breast cancer	0	0	7	29	1	4	7
09/02/18		ID1020 (TA513)		Obinutuzumab	Lymphoma	0	0	27	34	3	27	27

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
09/02/18		ID878 (TA511)		Brodalumab	Psoriasis	-	0	27	34	17	27	27
12/02/18		ID591 (TA512)		Tivozanib	Renal cancer	2	3	24	56	14	24	24
15/02/18		ID56 (TA516)	577	Cabozantinib	Thyroid cancer	0	0	-	0	-	21	26
01/03/18	19/03/18	ID1102 (TA517)		Avelumab	Skin cancer (merkel cell)	0	1	-11	31	7	8	10
05/03/18		3557		Lopinavir/ritonavir	HIV	-	3	-	0	-	3	24
05/03/18		3343		Lacosamide	Epilepsy	-	3	-	0	-	3	24
05/03/18		2418		Symtuza	HIV	0	3	3	45	4	3	24
08/03/18		ID1051 (TA518)		Tocilizumab	Arteritis	0	0	0	42	1	19	21
16/03/18	16/03/18	ID1019 (TA519)		Pembrolizumab	Urothelial cancer	0	4	3	59	10	11	20
22/03/18		3397		Levodopa-carbidopa intestinal gel	Parkinson's disease	3	14	7	28	-	6	21
22/03/18		3627		Misoprostol	Induction of labour	0	14	7	0	5	7	21
09/04/18		ID970 (TA520)		Atezolizumab	Lung cancer	0	3	8	38	7	16	3
27/04/18	27/04/18	ID1209 (TA522)		Pembrolizumab	Urothelial cancer	0	3	3	55	3	3	3
03/05/18		ID1075 (TA521)		Guselkumab	Psoriasis	0	0	0	49	5	26	6
04/05/18		ID894 (TA523)		Midostaurin	Leukaemia	4	7	0	48	12	25	6
04/05/18		ID446 (TA526)		Arsenic trioxide	Leukaemia	0	0	-	0	-	-	6
04/05/18		ID1366 (TA524)	1255	Brentuximab vedotin	Lymphoma	-	-	0	0	-	25	6
14/05/18		ID809	1510	Interferon beta 1a	Multiple sclerosis	-	11	-	-	2	-	11
14/05/18		ID809		Interferon beta 1b (Extavia)	Multiple sclerosis	-	3	3	-	2	-	11
14/05/18		ID809		Glatiramer acetate	Multiple sclerosis	-	3	-	-	2	-	11
17/05/18		ID1327 (TA525)		Atezolizumab	Urothelial cancer	0	0	0	39	1	12	8
01/06/18	01/06/18	ID1041 (TA528)		Niraparib	Ovarian cancer	0	0	3	25	7	20	19
06/06/18	06/06/18	ID1349 (TA531)		Pembrolizumab	Lung cancer	-	-	-	-	-	-	14
13/06/18		3293		Icatibant acetate	Angioedema	0	1	0	50	5	8	7
13/06/18		3233		Ranibizumab	Choroidal neovascularisation	0	1	0	50	5	8	7
13/06/18		700		Selexipag	Hypertension	0	1	0	50	5	8	7
22/06/18		ID937 (TA533)		Ocrelizumab	Multiple sclerosis	0	7	4	41	3	4	4
22/06/18		ID1048 (TA534)		Dupilumab	Atopic dermatitis	0	7	4	41	18	4	4
28/06/18		ID925 (TA536)		Alectinib	Lung cancer	0	4	19	35	1	27	11
29/06/18		ID1194 (TA537)		Ixekizumab	Psoriatic arthritis	0	3	18	34	4	27	10

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
05/07/18		ID1059 (TA535)	976	Lenvatinib	Thyroid cancer	-	-	-	-	-	-	4
05/07/18		ID1059 (TA535)	1416	Sorafenib	Thyroid cancer	-	4	-	28	11	8	4
12/07/18		ID910 (TA538)		Dinutuximab beta	Neuroblastoma	0	6	5	56	6	13	8
20/07/18		ID1224 (TA539)		Lutetium oxodotreotide	Neuroendocrine tumours	-	-	14	-	-	6	14
25/07/18	10/08/18	ID1062 (TA540)		Pembrolizumab	Lymphoma	0	6	7	55	6	7	20
23/07/18		2001		Dalbavancin	Skin infections	0	4	11	45	23	4	11
23/07/18		2037		Telotristat ethyl	Diarrhoea	0	4	11	45	23	8	11
23/07/18		1343		Ciprofloxacin	Ear infections	0	10	11	45	23	11	11
09/08/18		ID893 (TA541)		Inotuzumab ozogamicin	Leukaemia	7	7	7	28	7	8	21
23/08/18		ID1220 (TA543)		Tofacitinib	Psoriatic arthritis	0	0	15	42	11	6	7
24/08/18		ID1208 (TA542)		Cabozantinib	Renal cancer	0	0	14	41	10	5	6
05/09/18		ID1151 (HST8)		Burosumab	Hypophosphataemia	29	7	20	29	7	22	23
17/09/18		ID1226 (TA544)	1844	Dabrafenib	Melanoma	0	1	8	45	3	10	11
17/09/18		ID1226 (TA544)		Trametinib	Melanoma	0	1	8	45	3	10	11
20/09/18		3732		Octreotide	Neuroendocrine tumours	0	6	-	-	-	-	8
20/09/18		1988		Lanreotide	Neuroendocrine tumours	0	6	-	-	-	-	8
20/09/18		3582		Levonorgestrel	Contraception	-	4	6	42	6	7	8
01/10/18		ID1218 (TA547)		Tofacitinib	Ulcerative colitis	0	3	10	31	2	50	35
05/10/18		ID982 (TA545)		Gemtuzumab ozogamicin	Leukaemia	0	0	6	27	5	46	31
02/11/18		3604		Ipilimumab	Melanoma	-	11	12	34	11	25	21
02/11/18		1842		Semaglutide	Diabetes	0	10	12	34	12	25	21
02/11/18		786		Conestat alfa	Angioedema	0	11	12	34	11	25	21
08/11/18		ID1089 (TA551)		Lenvatinib	Liver cancer	0	5	6	28	5	20	20
08/11/18		ID1225 (TA552)		Liposomal cytarabine/daunorubicin	Leukaemia	0	5	6	28	5	20	20
19/11/18	20/11/18	ID1266 (TA553)		Pembrolizumab	Melanoma	72	30	44	37	6	8	28
22/11/18	22/11/18	ID1173 (TA557)		Pembrolizumab	Lung cancer	70	28	42	42	4	6	26
29/11/18		ID1519 (TA555)		Regorafenib	Liver cancer	0	0	11	0	1	1	19



Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Previous AWMSG ref	Medicine Name	Abbreviated Indication	Health Board formulary status ^#						
						ABMU	Aneurin Bevan	BCU	C&V	Cwm Taf	Hywel Dda	Powys
30/11/18	17/12/18	ID1316 (TA558)		Nivolumab	Melanoma	45	3	17	10	4	45	45
03/12/18		3414		Bictegravir/Emtricitabine/Tenofovir alafenamide	HIV	0	2	7	31	8	18	15
03/12/18		3789		Fosaprepitant	Nausea and vomiting	-	2	7	31	8	18	15
03/12/18		1882		Tiotropium	Asthma	-	2	7	31	8	18	15
07/12/18	19/12/18	ID1115 (TA559)		Axicabtagene ciloleucel	Lymphoma	43	43	37	43	20	43	43
19/12/18		3387		Brivaracetam	Epilepsy	0	2	-	15	2	2	9
19/12/18		2850		Dolutegravir/rilpivirine	HIV	0	2	15	43	2	2	43
04/01/19		ID1129		Benralizumab	Asthma	0	6	18	27	20	27	27
17/01/19		ID1227		Abemaciclib	Breast cancer	0	11	8	14	7	14	14
18/01/19		ID1097		Venetoclax	Leukaemia	13	7	7	13	10	13	13
18/01/19		ID923		Encorafenib	Melanoma	13	3	4	13	6	13	13
18/01/19		ID923		Binimetinib	Melanoma	13	3	4	13	6	13	13

\* Time to formulary addition from appraisal approval date should be within two months for AWMSG Health Technology Appraisals (including the orphan and ultra-orphan appraisal process), NICE Health Technology Appraisals and HSTs and cancer drugs. For NICE recommendations these should be following the first publication of the FAD or the FED for HSTs, and for AWMSG approvals following Welsh Government ratification.

^ Number of days from latest AWMSG/NICE approval statements and formulary status are data submitted by health board/trust. Where no number is provided this can generally be assumed to indicate that the medicine is "already on formulary" but for a different indication. However this is not always the case.

# The determination of formulary status is considered as the availability of the medicine to treat patients.

\* CAA (Commercial Access Agreement) Available Date information is provided by the all Wales Medicines Procurement Specialist Pharmacist

Key	
Green	On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
Yellow	On formulary. However the number of days stated is outside of the 60 day timescale.
White	Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 January 2019.
Red	Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 January 2019.
Blue	Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 31 January 2019. '-' indicates CAA is not yet available.

**Table 2. Velindre Cancer Centre medicines status**

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status					
					C+V	Powys*	ABMU*	Cwm Taf	ABUHB	VCC ONLY
11/01/2017		TA428	Pembrolizumab 2 <sup>nd</sup> line	Lung cancer	**	100	100	100	100	100
22/02/2017		TA432	Everolimus	Renal cancer	-	-	-	-	-	-
02/03/2017		ID794	Cetuximab	Colorectal cancer	-	-	-	-	-	-
02/03/2017		ID794	Panitumumab	Colorectal cancer	50	50	50	50	50	50
14/03/2017		1658	Triptorelin	Prostate cancer	38	38	38	38	38	38
12/05/2017		ID858	Everolimus	Neuroendocrine tumours	0	0	0	0	0	0
12/05/2017		ID858	Sunitinib	Neuroendocrine tumours	0	0	0	0	0	0
31/05/2017	28/07/2017	ID990	Pembrolizumab 1 <sup>st</sup> line	Lung cancer	**	1	1	1	1	1
09/06/2017	23/06/2017	ID959	Olaratumab	Sarcoma	4	4	4	4	4	4
15/06/2017	19/06/2017	ID1013	Trastuzumab Emtansine	Breast	6	6	6	6	6	6
10/07/2017		ID931 (TA463)	Cabozantinib	Renal cancer	0	0	0	0	0	0
04/08/2017		<u>ID1058</u>	Paclitaxel albumin-bound nanoparticles	Pancreatic cancer	0	0	0	0	0	0
08/08/2017		<u>ID1016</u>	Cetuximab	Head and neck cancer	10	10	10	10	10	10
10/08/2017		<u>ID1012</u>	Sorafenib	Liver cancer	0	0	0	0	0	0
20/09/2017	09/10/2017	<u>ID900</u>	Nivolumab	Lung cancer (non-squamous)	**	0	0	0	0	0
20/09/2017	09/10/2017	<u>ID811</u>	Nivolumab	Lung cancer (squamous)	**	0	0	0	0	0
13/10/2017		<u>ID971</u>	Nivolumab	Head and neck cancer (squamous)	0	0	0	0	0	0
01/11/2017		<u>ID939</u>	Atezolizumab	Urothelial cancer	24	24	24	24	24	24
19/10/2017		<u>976</u>	Lenvatinib	Thyroid cancer	4	4	4	4	4	4
16/11/2017		<u>ID1026</u>	Ribociclib	Breast cancer	21	21	21	21	21	21
16/11/2017		<u>ID915</u>	Palbociclib	Breast cancer	13	13	13	13	13	13
07/12/2017		ID1117	Ceritinib	Lung cancer	**	13	13	13	13	13
08/12/2017		ID1029 (TA498)	Levatinib	Renal Cell Carcinoma	54	54	54	54	54	54
01/02/2018	01/02/2018	ID523	Pertuzumab	Breast cancer	29	29	29	29	29	29
12/02/2018		ID591	Tivozanib	Renal cancer	56	56	56	56	56	56
15/02/2018		ID56	Cabozantanib	Thyroid cancer	0	0	0	0	0	0
01/03/2018	19/03/2018	ID1102	Avelumab	Merkel Cell	51	51	51	51	51	51
16/03/2018	16/03/2018	ID1019	Pembrolizumab	Urothelial cancer 2 <sup>nd</sup> line	46	46	46	46	46	46
09/04/2018		ID970	Atezolizumab 2 <sup>nd</sup> line	Lung Cancer	**	32	32	32	32	32

Appraisal Approval Date	CAA Available Date	AWMSG or NICE ref	Medicine name	Abbreviated indication	Health Board formulary status					
					C+V	Powys*	ABMU*	Cwm Taf	ABUHB	VCC ONLY
27/04/2018	27/04/2018	ID1209	Pembrolizumab	Urothelial cancer – platinum illegible	59	59	59	59	59	59
17/05/2018		ID1327	Atezolizumab	Urothelial cancer-	39	39	39	39	39	39
01/06/2018	01/06/2018	ID1041	Niraparib	Ovarian cancer	25	25	25	25	25	25
28/06/2018		ID925	Alectinib	Lung cancer	**	30	30	30	30	30
05/07/2018		ID1059 (TA535)	Lenvatinib	Thyroid cancer	0	0	0	0	0	0
05/07/2018		ID1059 (TA535)	Sorafenib	Thyroid cancer	0	0	0	0	0	0
20/07/2018		ID1224 (TA539)	Lutetium oxodotreotide	Neuroendocrine tumours	0	0	0	0	0	0
24/08/2018		ID1208 (TA542)	Cabozantinib	Renal cancer	0	0	0	0	0	0
17/09/2018		ID1226 (TA544)	Dabrafenib	Melanoma	45	45	45	45	45	45
17/09/2018		ID1226 (TA544)	Trametinib	Melanoma	45	45	45	45	45	45
08/11/2018		ID1089 (TA551)	Lenvatinib	Liver cancer	34	34	34	34	34	34
19/11/2018	20/11/2018	ID1266 (TA553)	Pembrolizumab	Melanoma	37	37	37	37	37	37
22/11/2018	22/11/2018	ID1173 (TA557)	Pembrolizumab	Lung cancer	**	39	39	39	39	39
29/11/2018		ID1519 (TA555)	Regorafenib	Liver cancer	13	13	13	13	13	13
30/11/2018	17/12/2018	ID1316 (TA558)	Nivolumab	Melanoma	0	0	0	0	0	0
03/12/2018		3789	Fosaprepitant	Nausea and vomiting	0	0	0	0	0	0
17/01/2019		ID1227	Abemaciclib	Breast cancer	14	14	14	14	14	14
18/01/2019		ID923	Encorafenib	Melanoma	13	13	13	13	13	13
18/01/2019		ID923	Binimetinib	Melanoma	13	13	13	13	13	13

\*Powys and Abertawe Bro Morgannwg also commission cancer services from other cancer providers. These dates relate to the Powys and Abertawe Bro Morgannwg populations that Velindre Cancer Centre are commissioned for and there may be variability with dates from other cancer service providers.

\*\* Cardiff and Vale UHB have their own lung service.

Key	Description
Green	On formulary. Where a number is stated this represents the number of days from AWMSG/NICE approval to formulary addition. '-' indicates that the medicine is already on formulary for the appraised indication. '[' indicates a medicine has been added to formulary in advance of the CAA being agreed; stated number is number of days from AWMSG/NICE approval.
Yellow	On formulary. However the number of days stated is outside of the 60 day timescale.
White	Not on formulary and within 60 days of approval date. Stated number is the number of days from AWMSG/NICE approval to 31 January 2019.
Red	Not on formulary and outside of 60 days since approval date. Stated number is the number of days from AWMSG/NICE approval to 31 January 2019.
Blue	Medicine is subject to a CAA. Stated number is the number of days from CAA availability to 31 January 2019. '-' indicates CAA is not yet available.